Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients

Abstract

Background Due to the limited accessibility of trastuzumab, the majority of Her2 positive breast cancer patients are treated mainly with systemic chemotherapy in Myanmar. This study aimed to find out the clinical outcome of treatment without trastuzumab for Her2 positive breast cancer patients. Methods A retrospective observational study of total 156 Her2 positive breast cancer patients not receiving anti-her2 therapy who diagnosed between January 2007 and December 2016 in two private oncology centers in Yangon, Myanmar. Results In this study, median age of patients was 52 years (25yrs-87yrs). Majority (80%, n = 126) were in early stage. Regarding treatment pattern, 99% of patients underwent..